1. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527–40.
2. Public Health Service Act. Available at http://www.fda.gov/regulatoryinformation/legislation/ucm148717.htm . Accessed 15 July 2016.
3. Federal Food Drug and Cosmetic Act. Available at http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact . Accessed 23 May 2016.
4. European Medicines Agebcey: Biosimilar Medicines. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp . Accessed 15 June 2016.
5. Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, Lu ZK, Love BL, Noxon V, Bobolts L, Armitage M, Bian J, Ray P, Ablin RJ, Hrushesky WJ, Macdougall IC, Sartor O, Armitage JO. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–605.